期刊
VACCINE
卷 27, 期 10, 页码 1579-1584出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.12.052
关键词
Neisseria meningitidis; 5CVMB vaccine; Genome-derived neisserial antigen (GNA); Sequencing; MLST
资金
- Orebro County Council Research Committee
- Foundation for Medical Research at Orebro University Hospital, Sweden
- Novartis VD, Italy
During the recent years, projects are in progress for designing broad-range non-capsular-based meningococcal vaccines, covering also serogroup B isolates. We have examined three genes encoding antigens (NadA, GNA1030 and GNA2091) included in a novel vaccine, i.e. the 5 Component Vaccine against Meningococcus B (5CVMB), in terms of gene prevalence and sequence variations. These data were combined with the results from a similar study, examining the two additional antigens included in the 5CVMB (fHbp and GNA2132). nadA and fHbp v. 1 were present in 38%(n = 36), respectively 71 %(n = 67)of the isolates, whereas gna2132, gna1030 and gna2091 were present in all the Neisseria meningitidis isolates tested (n = 95). The level of amino acid conservation was relatively high in GNA1030 (93%), GNA2091 (92%), and within the main variants of NadA and fHbp. GNA2132 (54% of the amino acids conserved) appeared to be the most diversified antigen. Consequently, the theoretical coverage of the 5CVMB antigens and the feasibility to use these in a broad-range meningococcal vaccine is appealing. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据